Key Highlights

  • Up 9.73 percent to USD 1.24 in pre-market trading on November 2, 2026.
  • No company announcement dated November 2, 2026 was identified.
  • Nasdaq issued a delisting determination on July 15, 2026 over a stockholders' Equity shortfall.
  • Reported equity was USD 2,091,324 against a USD 2.5 million requirement.
  • The company has asked a Nasdaq panel to confirm compliance; no panel decision was identified.

What Moved Caring Brands Shares Pre-Market

Caring Brands (NASDAQ:CABR) was up 9.73 percent to USD 1.24 in pre-market trading on November 2, 2026. No press release or regulatory filing dated November 2, 2026 was identified.

With no stated catalyst, the gain looks consistent with speculative trading in a low-priced, small-capitalization name. Short-interest and listing-status headlines have circulated in recent weeks, but the company itself has not announced new information that explains the move.

The Nasdaq Delisting Determination

In a Form 8-K filed on July 17, 2026, the company disclosed that Nasdaq staff found it out of compliance with Listing Rule 5550(b). Stockholders' equity of USD 2,091,324 was below the USD 2.5 million minimum, and the company also missed the alternative Market Value and Net Income tests.

The company first received notice on April 7, 2026, and the staff determination followed on July 15, 2026. Staff said the plan to amend the Series A preferred stock and secure financing lacked a definitive agreement. The company then asked a Nasdaq Hearings Panel to confirm it had regained compliance, citing preliminary pro forma stockholders' equity of USD 8,220,419 as of August 31, 2026 after private Placement closings. No panel decision was identified, and the company cautioned there is no assurance the panel will agree.

Business Background And Financing

Caring Brands, based in Fort Pierce, Florida, focuses on licensing and developing consumer health products. Company releases this year have covered an exclusive global license for the Emesyl nausea relief product dated January 2026, patents for a hair enzyme product in February 2026, and an intellectual property update dated August 6, 2026.

The company has also raised capital through offerings and a private placement, including an initial USD 4.6 million closing under a planned USD 9 million placement. The Quarterly Report showed cash of USD 1,820,365 at June 30, 2026 and only minimal Revenue to date.

Balance Sheet And Risks

Listing compliance is the central risk. If the panel does not grant continued listing, the shares could be Delisted from Nasdaq, which would likely reduce liquidity.

As a penny stock, the shares can be highly volatile and thinly traded, and repeated equity financings carry dilution risk for existing holders.

What To Watch Next

Investors may look for the panel decision and any definitive agreement on the Series A preferred stock amendment. New financing terms or licensing revenue disclosures would also matter.

Nasdaq said it will monitor compliance at the next periodic report, the quarterly filing for the period ending September 30, 2026.